UK-based drug discovery and development company e-Therapeutics (AIM: ETX) has announced the appointment of Steve Medlicott as Finance Director.
Mr Medlicott joins e-Therapeutics’ management team having previously advised the Company in its £40m fundraising in 2013.
Mr Medlicott held key business development and sell-side analyst roles with Peel Hunt, N+1 Singer, Altium Capital and Williams de Broe. He was voted the top Industrials analyst in the Thomson Reuters Extel survey numerous times, and was the top Pan-European Industrials analyst in the 2011 Reuters Starmine Awards. He co-founded Blueprint Advisors in 2012.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze